Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/177 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME14603583
PMID: | 14603583
LR: | 20051116
CED: | 20031107
DCO: | 20031118
Autoren: | McAlindon T
Titel: | Why are clinical trials of glucosamine no longer uniformly positive?
Quelle: | Rheumatic diseases clinics of North America; VOL: 29 (4); p. 789-801 /200311/
PM: | Print
SU: | IM
Sprache: | English
CY: | United States
JID: | 8708093
ISSN: | 0889-857X
CO: | RDCAEK
Institution: | Division of Rheumatology, Tufts-New England Medical Center, Box 406, 750 Washington Street, Boston, MA 02111, USA. tmcalindon@tufts-nemc.org
DT: | Journal Article; Review
RN: | 42
Schlagwörter
CT: | CLINICAL TRIALS; CONFLICT OF INTEREST; GLUCOSAMINE/*pharmacology; HUMANS; KNEE JOINT/pathology; OSTEOARTHRITIS/*drug therapy; OSTEOARTHRITIS/pathology; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME
CTG: | KLINISCHE STUDIEN; INTERESSENKONFLIKT; GLUCOSAMIN/*Pharmakologie; MENSCH; KNIEGELENK/Pathologie; OSTEOARTHROSE/*Arzneimitteltherapie; OSTEOARTHROSE/Pathologie; FORSCHUNGSDESIGN; STICHPROBENGRÖßE; BEHANDLUNGSERGEBNIS
TE: | Glucosamine/3416-24-8
CR: | 3416-24-8
AB: | In contrast to earlier industry-funded trials of for knee OA, recent studies have generated negative results. While there will be a tendency to assume that these studies were negative because of the absence of any conflicts of interest, a number of issues must be taken into consideration before drawing such conclusions. These issues include design issues and important differences in sample characteristics. Ultimately, it is clear that more work needs to be done to clarify issues surrounding the efficacy and utility of the various glucosamine compounds.

» Volltext »
» Fenster schließen »